VentriPoint Diagnostics Ltd. — News

Proposed collaboration would combine UniDoc Health Cubes and connected-care infrastructure with Ventripoint's AI-enabled VMS+™ platform in a hub-and-spoke care model   Toronto, Ontario – TheNewswire – August 5, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT; OTC:VPTDF) a leader in AI-powered cardiac imaging, is pleased to announce that it has signed a memorandum of understanding ("MOU") with UniDoc Health Corp. ("UniDoc") to evaluate a potential collaboration focused on remote cardiac assessment and cardiovascular screening.

thenewswire.com - 2026-08-05 08:30:00

Toronto, Ontario – July 29, 2026 – TheNewswire - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV: VPT; OTC: VPTDF), a leader in AI-powered cardiac imaging, today announced the appointment of Dr. Philip M. Toleikis to its Board of Directors, adding extensive public company leadership, capital markets expertise, and medical technology commercialization experience as the Company accelerates the global expansion of its VMS+ cardiac imaging platform.   Dr. Toleikis is a seasoned life sciences executive with a proven track record of building innovative healthcare companies, securing capital, developing strategic partnerships, and creating shareholder value. His appointment further strengthens Ventripoint's governance as the Company advances commercial execution and positions itself for growth.

thenewswire.com - 2026-07-29 16:55:00

Toronto, Ontario – TheNewswire - July 22, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces it will satisfy debenture interest payment obligations with the issuance of common shares, subject to TSX Venture Exchange (“ TSXV ”) approval. The Corporation will issue an aggregate of 601,115 common shares (“ Shares ”) for the payment of an aggregate of $72,143  of interest owing on certain outstanding Convertible Debentures issued by the Corporation on May 10, 2024, June 28, 2024 and December 16, 2024 . The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of ($0.12), subject to the approval of TSXV, and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation.   About Ventripoint Diagnostics Ltd.

thenewswire.com - 2026-07-22 16:30:00

Pioneering Medical AI Company Moves to Increase Awareness of VMS+ System and Proprietary Knowledge Based Reconstruction Technology   Toronto, Ontario – TheNewswire – July 22, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, is pleased to announce that it has engaged More Capital Ltd. ("More Capital"), a Toronto, Ontario-based private investment and strategic advisory firm, under a strategic growth and advisory agreement focused on commercial partnerships, market expansion and broader awareness of the Company's technology, subject to acceptance by the TSX Venture Exchange ("TSX-V").

thenewswire.com - 2026-07-22 08:05:00

Ventripoint's VMS+ platform to be evaluated alongside a second AI technology in a landmark NHS study exploring earlier detection of chemotherapy-related heart damage   Toronto, Ontario – TheNewswire – July 20, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a leader in the application of artificial intelligence to echocardiography, today announced that its VMS+ technology has been selected for use in AIRES (Artificial Intelligence Reconstruction of Echocardiography Study), a newly launched clinical research study at The Royal Wolverhampton NHS Trust (RWT) in the United Kingdom.

thenewswire.com - 2026-07-20 10:50:00

Collaboration inspired by families' lived experiences aims to reduce barriers to advanced cardiac imaging and ensure no parent faces impossible decisions when seeking answers about their child's heart.     Toronto, Ontario – TheNewswire – June 26, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, today announced a strategic collaboration with Ollie Hinkle Heart Foundation (OHHF) to expand access to AI-powered cardiac imaging and clinical decision-support technology for children and adults living with congenital and childhood-onset heart disease.

thenewswire.com - 2026-06-26 08:10:00

Toronto, Ontario – TheNewswire – June 15, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, today announced its support for the Global Congenital Heart Disease Alliance (“GCHDA”), a newly forming industry alliance dedicated to accelerating the development, commercialization, and global adoption of congenital cardiovascular technologies.   GCHDA brings together industry partners, clinicians, researchers, regulators, investors, and patient communities to address the unique challenges facing innovators in congenital heart disease (CHD) - the most common birth defect in the world. Through membership and advocacy programs, multi-center research collaboration, and a convening platform of summits and innovation showcases, GCHDA aims to build a unified support ecosystem for a field that has long been fragmented.

thenewswire.com - 2026-06-15 08:10:00

Ventripoint Diagnostics Ltd. (VPT:CA) Shareholder/Analyst Call Transcript

seekingalpha.com - 2026-06-03 02:42:00

Toronto, Canada – TheNewswire - May 25, 2026 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") ( TSXV:VPT; OTC:VPTDF ), a leading provider of innovative AI-powered cardiac diagnostic solutions, is pleased to provide a videoconference link for its Annual General Meeting, which will be followed by a corporate update.   Shareholder Videoconference:

thenewswire.com - 2026-05-25 08:10:00

Toronto, Ontario, May 22, 2026 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint” or the “Corporation ”) (TSXV:VPT) is pleased to announce the closing of a non-brokered private placement of 2,800,273 units (each, a “Unit”) at a price of $0.11 per Unit for aggregate gross proceeds of $308,030 (the “Offering”), subject to TSXV Venture Exchange (the “Exchange”) acceptance. Each Unit will be comprised of one (1) common share (“Common Shares”) of the Corporation, and one (1) common share purchase warrant (“Warrants”).   E ach whole Warrant will entitle the holder thereof to purchase one (1) Common Share at a price of $0.14 for a period of 24 months from the closing of the Offering.

thenewswire.com - 2026-05-22 17:00:00

Toronto, Ontario – TheNewswire - May 19 , 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “ Corporation ”, TSXV:VPT) announces it has received approval from the TSX Venture Exchange (“ TSXV ”) and issued of 555,699 common shares (“ Shares ”) for the payment of an aggregate of $61,217 of interest owing on certain outstanding Convertible Debentures issued by the Corporation on September 20, 2024, March 21, 2025, September 2, 2025, and October 14, 2025. The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of $0.11 and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation.   The Offering is a related party transaction within the meaning of TSXV Policy 5.9 and Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI-61-101”) as certain insiders of the Corporation received an aggregate of 15,778 Shares. The Corporation is relying on exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and (b) and 5.7(a) and (b) of MI 61-101, as the Corporation is not listed on a specified market and the fair market value of the participation in the transactions by insiders does not exceed 25% of the market capitalization of the Corporation, as determined in accordance with MI 61-101 and the fair market value of the transactions is not more than $2,500,000.

thenewswire.com - 2026-05-19 08:25:00

The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026

gurufocus.com - 2026-05-12 11:00:00